LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: Metronomic Maintenance With Weekly Vinblastine After Induction With Bevacizumab-Irinotecan in Children With Low-grade Glioma Prevents Early Relapse.

    Roux, Clémence / Revon-Rivière, Gabriel / Gentet, Jean Claude / Verschuur, Arnauld / Scavarda, Didier / Saultier, Paul / Appay, Romain / Padovani, Laetitia / André, Nicolas

    Journal of pediatric hematology/oncology

    2020  Volume 43, Issue 5, Page(s) e630–e634

    Abstract: Background: Pediatric low-grade glioma (pLGG) represents the most common brain tumor in childhood. Previous studies have reported that a therapeutic strategy on the basis of the association of bevacizumab alone (B) or in combination with irinotecan (BI) ...

    Abstract Background: Pediatric low-grade glioma (pLGG) represents the most common brain tumor in childhood. Previous studies have reported that a therapeutic strategy on the basis of the association of bevacizumab alone (B) or in combination with irinotecan (BI) could produce rapid tumor response and clinical improvement in children with pLGG. Nevertheless, a majority of patients relapses shortly (median, 5 mo) after stopping B or BI treatment. We proposed metronomic maintenance with weekly vinblastine added after a 6 months induction of B/BI to prevent early relapse.
    Patients and methods: Monocentric retrospective analysis of a patient with pLGG treated with B or BI for 6 months followed by a 12-month maintenance with weekly vinblastine (6 mg/m²) from October 2012 to September 2019 in a single institution.
    Results: In total, 18 patients (7 males and 11 females) were identified. Because of progression during the B or BI induction 2/18 children were excluded. In total, 16 patients were analyzed with a median age of 10 years (range, 4 to 16 y). A total of 13 patients received BI and 3 patients received B alone. The mean duration of induction was 6.2 months (range, 2 to 12 mo). After induction 5/16 patients had a partial radiologic response, 11/16 patients had stable disease. All patients started maintenance (median duration, 12 mo; range, 3 to 12 mo). With a median follow-up of 3.9 years after the end of B or BI (range, 11 mo to 7.2 y), 15/16 patients were alive and 9/16 patients were progression-free. Seven of 16 children progressed with a median time to progression of 23 months (ranges, 5 to 39 mo). Three of 16 (18%) children progressed during vinblastine maintenance and 4/16 (25%) patients after the end of maintenance. After the total duration of treatment, clinical improvement was noted in 4 patients, 9 patients had stable symptoms, and only 3 patients progressed. One and 2-year event-free survival were, respectively, 81.2% and 56.2%. Two-year overall survival was 93.7%.
    Conclusions: We report here, the potential benefit and the improvement of progression-free survival by adding metronomic maintenance with weekly vinblastine after initial induction with B or BI in children with low-grade glioma.
    MeSH term(s) Administration, Metronomic ; Adolescent ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bevacizumab/administration & dosage ; Bevacizumab/therapeutic use ; Brain Neoplasms/drug therapy ; Brain Neoplasms/pathology ; Child ; Child, Preschool ; Female ; Glioma/drug therapy ; Glioma/pathology ; Humans ; Irinotecan/administration & dosage ; Irinotecan/therapeutic use ; Male ; Neoplasm Recurrence, Local/pathology ; Neoplasm Recurrence, Local/prevention & control ; Retrospective Studies ; Vinblastine/administration & dosage ; Vinblastine/therapeutic use
    Chemical Substances Antineoplastic Agents ; Bevacizumab (2S9ZZM9Q9V) ; Vinblastine (5V9KLZ54CY) ; Irinotecan (7673326042)
    Language English
    Publishing date 2020-11-23
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1231152-2
    ISSN 1536-3678 ; 1077-4114 ; 0192-8562
    ISSN (online) 1536-3678
    ISSN 1077-4114 ; 0192-8562
    DOI 10.1097/MPH.0000000000002002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Immunosuppressive Mesenchymal Stromal Cells Derived from Human-Induced Pluripotent Stem Cells Induce Human Regulatory T Cells

    Roux, Clémence / Saviane, Gaëlle / Pini, Jonathan / Belaïd, Nourhène / Dhib, Gihen / Voha, Christine / Ibáñez, Lidia / Boutin, Antoine / Mazure, Nathalie M / Wakkach, Abdelilah / Blin-Wakkach, Claudine / Rouleau, Matthieu

    Frontiers in immunology

    2017  Volume 8, Page(s) 1991

    Abstract: Despite mesenchymal stromal cells (MSCs) are considered as a promising source of cells to modulate immune functions on cells from innate and adaptive immune systems, their clinical use remains restricted (few number, ... ...

    Abstract Despite mesenchymal stromal cells (MSCs) are considered as a promising source of cells to modulate immune functions on cells from innate and adaptive immune systems, their clinical use remains restricted (few number, limited
    Language English
    Publishing date 2017
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2606827-8
    ISSN 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2017.01991
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Single-Unit versus Double-Unit Umbilical Cord Blood Transplantation in Children and Young Adults with Residual Leukemic Disease.

    Balligand, Laura / Galambrun, Claire / Sirvent, Anne / Roux, Clémence / Pochon, Cecile / Bruno, Benedicte / Jubert, Charlotte / Loundou, Anderson / Esmiol, Sophie / Yakoub-Agha, Ibrahim / Forcade, Edouard / Paillard, Catherine / Marie-Cardine, Aude / Plantaz, Dominique / Gandemer, Virginie / Blaise, Didier / Rialland, Fanny / Renard, Cecile / Seux, Mylene /
    Baumstarck, Karine / Mohty, Mohamad / Dalle, Jean-Hugues / Michel, Gérard

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

    2018  Volume 25, Issue 4, Page(s) 734–742

    Abstract: We previously reported in a French prospective randomized study that transplantation of 2 unrelated cord blood (UCB) units instead of 1 unit does not decrease the risk of transplantation failure but may enhance alloreactivity. Here we evaluated the ... ...

    Abstract We previously reported in a French prospective randomized study that transplantation of 2 unrelated cord blood (UCB) units instead of 1 unit does not decrease the risk of transplantation failure but may enhance alloreactivity. Here we evaluated the influence of pretransplantation minimal residual disease (MRD) on leukemia relapse and survival after single- versus double-UCB transplantation (UCBT). Among 137 children and young adults who underwent UCBT in this randomized study, 115 had available data on MRD assessment done immediately before initiation of the pretransplantation conditioning regimen. MRD was considered positive at a level of ≥10
    MeSH term(s) Adult ; Cord Blood Stem Cell Transplantation/methods ; Female ; Humans ; Leukemia, Myeloid, Acute/therapy ; Male ; Prospective Studies ; Young Adult
    Language English
    Publishing date 2018-10-29
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1474865-4
    ISSN 1523-6536 ; 1083-8791
    ISSN (online) 1523-6536
    ISSN 1083-8791
    DOI 10.1016/j.bbmt.2018.10.016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working group.

    Roos-Weil, Damien / Nguyen-Khac, Florence / Chevret, Sylvie / Touzeau, Cyrille / Roux, Clémence / Lejeune, Julie / Cosson, Adrien / Mathis, Stéphanie / Feugier, Pierre / Leprêtre, Stéphane / Béné, Marie-Christine / Baron, Marine / Raynaud, Sophie / Struski, Stéphanie / Eclache, Virginie / Sutton, Laurent / Lesty, Claude / Merle-Béral, Hélène / Cymbalista, Florence /
    Ysebaert, Loïc / Davi, Frédéric / Leblond, Véronique

    Genes, chromosomes & cancer

    2018  Volume 57, Issue 11, Page(s) 533–540

    Abstract: Trisomy 12 (tri12) is the second most frequent chromosomal aberration (15%-20%) in chronic lymphocytic leukemia (CLL). Tri12 confers an intermediate prognosis but is a heterogeneous entity. We examined whether additional mutational or chromosomal ... ...

    Abstract Trisomy 12 (tri12) is the second most frequent chromosomal aberration (15%-20%) in chronic lymphocytic leukemia (CLL). Tri12 confers an intermediate prognosis but is a heterogeneous entity. We examined whether additional mutational or chromosomal alterations might impact tri12 patient outcomes. This retrospective study, carried out by the French Innovative Leukemia Organization, included 188 tri12 patients with comprehensive information on immunoglobulin heavy chain (IGHV) gene status, karyotypic/FISH abnormalities, and NOTCH1, TP53, SF3B1, and MYD88 mutations. The main cytogenetic abnormalities associated with tri12 were del(13q) (25%), additional trisomies (14%) (including tri19 (10%) and tri18 (4%)), 14q32 translocations (10%), del(17p) (6.5%), del(14q) (4%), and del(11q) (4%). Unmutated (UM) IGHV, NOTCH1, and TP53, mutations were identified in respectively 66%, 25%, and 8.5% of cases. Multivariate analyses showed that additional trisomies (HR = 0.43, 95% CI = 0.23-0.78, P = .01) were associated with a significantly longer time to first treatment in Binet stage A patients and with a lower risk of relapse (HR = 0.37, 95% CI = 0.15-0.9, P = .03) in the overall tri12 population. Binet stage B/C, TP53 disruption, and UM IGHV status were associated with a shorter time to next treatment, while Binet stage B/C (HR = 4, 95% CI = 1.6-4.9, P = .002) and TP53 disruption (HR = 5, 95% CI = 1.94-12.66, P = .001) conferred shorter overall survival in multivariate comparisons. These data indicate that additional cytogenetic and mutational abnormalities, and particularly additional trisomies, IGHV status, and TP53 disruption, influence tri12 patient outcomes and could improve risk stratification in this population.
    MeSH term(s) Aged ; Chromosomes, Human, Pair 12/genetics ; Cytogenetic Analysis ; DNA Mutational Analysis ; Female ; France/epidemiology ; Humans ; Immunoglobulin Heavy Chains/genetics ; Leukemia, Lymphocytic, Chronic, B-Cell/epidemiology ; Leukemia, Lymphocytic, Chronic, B-Cell/genetics ; Male ; Middle Aged ; Retrospective Studies ; Trisomy/genetics
    Chemical Substances Immunoglobulin Heavy Chains
    Language English
    Publishing date 2018-09-11
    Publishing country United States
    Document type Journal Article ; Multicenter Study
    ZDB-ID 1018988-9
    ISSN 1098-2264 ; 1045-2257
    ISSN (online) 1098-2264
    ISSN 1045-2257
    DOI 10.1002/gcc.22650
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase.

    Roux, Clémence / Nicolini, Franck-Emmanuel / Rea, Delphine / Niault, Mathilde / Mollica, Luigina / Berger, Françoise / Chassagne-Clément, Catherine / Tigaud, Isabelle / Tulliez, Michel / Giraudier, Stéphane / Turhan, Ali / Rousselot, Philippe / Legros, Laurence

    Blood

    2013  Volume 122, Issue 17, Page(s) 3082–3084

    MeSH term(s) Adult ; Aged ; Antineoplastic Agents/adverse effects ; Chronic Disease ; Dasatinib ; Drug Administration Schedule ; Drug Substitution ; Humans ; Hyperplasia/chemically induced ; Hyperplasia/pathology ; Karyotyping ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology ; Lymph Nodes/drug effects ; Lymph Nodes/pathology ; Middle Aged ; Protein Kinase Inhibitors/adverse effects ; Pyrimidines/adverse effects ; Thiazoles/adverse effects
    Chemical Substances Antineoplastic Agents ; Protein Kinase Inhibitors ; Pyrimidines ; Thiazoles ; Dasatinib (RBZ1571X5H)
    Language English
    Publishing date 2013-10-23
    Publishing country United States
    Document type Letter
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood-2013-07-513879
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities.

    Wanquet, Anne / Prebet, Thomas / Berthon, Céline / Sebert, Marie / Roux, Clémence / Kulasekararaj, Austin / Micol, Jean-Baptiste / Esterni, Benjamin / Itzykson, Raphael / Thepot, Sylvain / Recher, Christian / Delaunay, Jacques / Dreyfus, François / Mufti, Ghulam / Fenaux, Pierre / Vey, Norbert

    American journal of hematology

    2015  Volume 90, Issue 10, Page(s) 859–863

    Abstract: Acute Myeloid Leukemia (AML) and myelodysplasia (MDS) with chromosome 3q abnormalities have a dismal outcome either untreated or with conventional treatments. Azacitidine (AZA) is now considered as the standard of care in high-risk MDS and oligoblastic ... ...

    Abstract Acute Myeloid Leukemia (AML) and myelodysplasia (MDS) with chromosome 3q abnormalities have a dismal outcome either untreated or with conventional treatments. Azacitidine (AZA) is now considered as the standard of care in high-risk MDS and oligoblastic AML patients. The objective of this study was to evaluate the impact of azacitine treatment in this cytogenetic subgroup. We report here a multicentre retrospective study of 157 patients treated with AZA for AML/MDS with chromosome 3q abnormalities and 27 patients with isolated EVI-1 overexpression. Median age was 65 years, 40 patients (25%) had inv(3)(q21q26.2) or t(3;3)(q21;q26.2), 36 patients (23%) had other balanced 3q26 rearrangements, 8 patients (5%) had balanced 3q21 rearrangements and 73 patients (46%) had other 3q abnormalities. The overall response rate was 50% (29% CR). Median overall survival was 10.6 months. By multivariate analysis, patients with lower bone marrow blast counts, higher platelet counts, non-complex cytogenetics, and absence of prior treatment with intensive chemotherapy had a better outcome. 27 patients were allo-transplanted and achieved a 21-month median OS. Balanced 3q21 translocations were associated with a better response rate and overall survival. Outcome of patients with isolated EVI-1 overexpression was comparable to that of patients with chromosome 3q lesions. Thus, AML/MDS patients with 3q abnormalities appear to be a heterogeneous group in their response to AZA, and AZA may represent a suitable option in particular as a bridge to allogeneic transplantation.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Allografts ; Antimetabolites, Antineoplastic/administration & dosage ; Azacitidine/administration & dosage ; Blast Crisis/genetics ; Blast Crisis/mortality ; Blast Crisis/therapy ; Chromosome Aberrations ; Chromosomes, Human, Pair 3/genetics ; Disease-Free Survival ; Female ; Humans ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/mortality ; Leukemia, Myeloid, Acute/therapy ; Male ; Middle Aged ; Myelodysplastic Syndromes/genetics ; Myelodysplastic Syndromes/mortality ; Myelodysplastic Syndromes/therapy ; Retrospective Studies ; Stem Cell Transplantation ; Survival Rate
    Chemical Substances Antimetabolites, Antineoplastic ; Azacitidine (M801H13NRU)
    Language English
    Publishing date 2015-10
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 196767-8
    ISSN 1096-8652 ; 0361-8609
    ISSN (online) 1096-8652
    ISSN 0361-8609
    DOI 10.1002/ajh.24099
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top